In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sigilon Therapeutics Inc.

sigilon.com

Latest From Sigilon Therapeutics Inc.

Vertex Buys Semma, Gaining Cell Therapy-Based Type 1 Diabetes Treatments

Semma's innovative technology involves growing insulin-producing beta cells from stem cells and transplanting them into the liver, but it hasn't been tested in humans yet.

Deals Metabolic Disorders

Arrakis Pivots From Platform To Pipeline With $75m For RNA-Targeting Small Molecules

CEO Michael Gilman, who now helms the company full time, said Arrakis will use its Series B venture capital funding to build a pipeline of drug candidates, primarily in cancer, with the goal of taking its first medicines into the clinic in the next two to three years.
Financing StartUps and SMEs

Partnering In Cell And Gene Therapy Is A Unique Endeavor

Industry and academic representatives shared viewpoints at Biotech Week Boston in September 2018, including what is unique about deal-making in the cell and gene field.

Regenerative Medicine Deals

Appointments: Senior Hires At Allergan, Novartis, Array Biopharma, Zelluna Immunotherapy, Grail, Alzheon And Sigilon Therapeutics

Pfizer Oncology has lost its CMO to Allergan, while Novartis beefs up its ethical leadership, Array Biopharma appoints a new chair and Sigilon raids Bioverativ for its new CEO.

Appointments Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Sigilon Therapeutics Inc.
  • Senior Management
  • Rogerio Vivaldi, MD, CEO
    Glenn Reicin, CFO
    David E Moller, MD, CSO
    James D Watson, CBO
    Deya Corzo, MD, CMO
  • Contact Info
  • Sigilon Therapeutics Inc.
    Phone: (617) 336-7540
    100 BInney St.
    Ste. 600
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register